Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from OncoSil Medical Ltd ( (AU:OSL) ).
OncoSil Medical Limited has successfully completed its first hot production test run at its Sydney manufacturing facility, marking a significant milestone in its manufacturing capabilities. This achievement demonstrates the facility’s ability to produce the OncoSil™ device under full production conditions, supporting the company’s regulatory review process and strategy to enhance supply chain resilience. The new facility is expected to improve manufacturing efficiencies and reduce production costs, potentially increasing product margins, subject to regulatory approval and operational performance.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Limited is a global medical device company specializing in interventional oncology. The company focuses on improving cancer treatment outcomes through the intratumoural placement of Phosphorous-32 (32P) Microparticles, complementing chemotherapy. OncoSil Medical has developed the OncoSil™ device specifically for treating unresectable locally advanced pancreatic cancer, offering a targeted approach that delivers higher radiation doses directly to tumors while minimizing exposure to surrounding organs. The device has received CE Marking approval and is designated as a breakthrough device in Europe and the United States, with approval for sale in over 30 countries.
Average Trading Volume: 24,482
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$19.93M
For an in-depth examination of OSL stock, go to TipRanks’ Overview page.